Buzz: Potential BioMarin buyout looms with GSK, Shire in running

Here's some M&A scuttlebutt: The Guardian reports that traders tell the newspaper that a buyout of rare disease drug specialist BioMarin ($BMRN) "could come soon." GlaxoSmithKline ($GSK) and Shire ($SHPGY), two U.K. drugmakers with existing footholds in rare diseases, have been rumored to be considering bids for BioMarin, the newspaper reports. How much would bidders be willing to pay for BioMarin? Estimates run as high as $7 billion. London-based GSK has already been trying to wear down a reticent board of Human Genome Sciences ($HGSI) to acquire the U.S. biotech. Report

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.